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SCOPE OF REPORT 
This report takes account of the views and experiences of participants on the Royal Pharmaceutical 
Society Wales’ (RPS) Leadership Programme which included a ‘Patient Impact Project’. It is based on 
our analysis of data from questionnaires and a discussion group, all from the period January- April 
2011. This evaluation needs to be seen alongside other evaluations of the broader programme.  
As with any such research project, this study was only possible thanks to the contributions of the 
participants. Their willing engagement with the study, openness and honesty is gratefully 
acknowledged. The report uses a thematic approach to analyse the different sources of data 
presented during the course of the evaluation. Conclusions are based on our understanding of the 
evidence presented to us by the respondents and any errors of interpretation are solely due to the 
authors.  
Dr Mark Llewellyn and Professor Marcus Longley | May 2011 
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1 | INTRODUCTION AND METHODOLOGY 
1.1 INTRODUCTION 
The Welsh Institute for Health and Social Care (WIHSC), University of Glamorgan was commissioned to 
evaluate part of the Royal Pharmaceutical Society Wales’ (RPS) Leadership Programme. Twenty-seven 
pharmacists took part in the programme, which included a series of Action Learning Sets and a Patient 
Impact Project (PIP). WIHSC’s commission was focused on understanding the impact that the PIPs have 
achieved, and the challenges in delivering them. 
1.2 METHODOLOGY 
WIHSC took a qualitative approach to the evaluation in order to ensure that a deep understanding of 
the themes and issues arising was reached. Essentially, data was gathered from two principal sources: 
Online questionnaire 
The 27 pharmacist participants were asked to complete an online questionnaire in order to identify 
the impact that their PIP had made, and to provide more general comment on the course and the 
changes they identified for themselves after the sessions. 25 of the 27 participants completed the 
survey – a response rate of 93%. A list of the questions asked is contained in Appendix 1.  
‘Response to findings’ workshop 
In order to gain further insight into the views of the respondents, the interim findings were 
presented at a workshop, held at RPS Wales on 14th April. This presentation was followed by a 
period of deliberation wherein respondents were asked to consider the implications of the impact 
of their PIPs, as well as to think through how best to ‘future-proof’ the programme. 
1.2.1 Analysis  
A thematic strategy was employed to analyse the data. Answers were coded equally on the basis of 
what they said; none of the responses were weighted as more significant than any others and so all 
views are comparable in terms of their importance. Hereafter we review the sentiments and 
judgements of the evaluation respondents according to their comments. Verbatim quotations (in 
italics) are used to capture recurrent, or otherwise resonant, points of view. WIHSC does not 
necessarily endorse the opinions in question – quotations are only used to portray viewpoints 
accurately and clearly. The report is obviously not a verbatim transcript but an exploration of the 
themes and issues raised by respondents through the consultation process. So whilst encapsulating the 
main themes and highlighting the key points, the document seeks to be faithful to what was said by 
participants. To that end and in order to vividly hear the voices of respondents, the report deliberately 
includes a large number of quotations with relatively little by the way of comment or interpretation. 
Certain details have been removed from quotations in order to preserve anonymity. 
1.2.2 Report structure 
The structure of the following chapters mirrors that of the methodological approach as described 
above. Chapter 2 provides an account of the answers given to the online questionnaire, and Chapter 3 
provides conclusions based on the discussions held at the workshop in April. The report ends with a 
number of areas for further consideration in the light of the evidence presented. 
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2 | RESEARCH FINDINGS 
This chapter reports the findings from the online questionnaire that 25 of the 27 programme 
participants completed. There were two main sections to the survey: the first considered the 
outcomes from their PIP; and the second asked respondents to reflect more on the programme as a 
whole, and its impact on their professional practice. In order to hear the voices of the respondents as 
clearly and vividly as possible, the following sections deliberately provide a large number of quotations 
from participants with little by the way of  interpretation. 
2.1 EVALUATING THE PATIENT IMPACT PROJECT (PIP) 
Participants were asked to comment on how far the projects had delivered against the original aims 
and objectives. Respondents were very forthcoming and candid in sharing their own stories and 
experiences. 
2.1.1 Overall impact on patients 
In terms of overall impact, a number of themes emerged from the analysis.  
Better professional practice 
The major impact identified by respondents was that the PIP had helped to improve and sharpen up 
their professional practice – whether in terms of compliance, Medicine Use Reviews (MURs), the 
cessation of unnecessary therapies and a range of other issues: 
Patients are now counselled appropriately on how to use their device 
In some cases patients have been found to be on inhalers that were not needed and subsequently 
stopped therapy 
The project has resulted in patients on [medication] being actively targeted for an MUR and an 
increased understanding of community pharmacists of the pathway patients take through the 
service.  This will enable them to have more effective and understanding discussions with patients 
and should therefore result in a better MUR  
[The medication] is now reviewed daily, and stopped for patients who no longer require it 
The embedding of good practice in healthcare settings and raising the profile in relation to safety 
aspects of [the medication] has improved the overall safety of patients. Patients' medicines are 
managed better from both a prescribing and dispensing perspective improving safety for patients 
Having a pharmacist working as part of the clinical team allows dose amendments, the addition or 
deletion of items, drug therapy optimisation and advice on future medication management to 
occur early during the patients’ admission 
Ensuring medication is appropriately prescribed when admitted to hospital, reducing waste 
The project has highlighted over ordering/oversupply of medications on repeat and has sought to 
address that by either directly altering the repeat medicine or requesting the patient attends the 
practice for a disease review. An example was one patient was identified who was receiving four 
inhalers per month where one would have sufficed, the quantity on repeat was immediately 
reduced and the practice made aware. The patient was then called in for a review with the GP and 
the issue resolved 
 Evaluation of Patient Impact Projects for RPS Wales | May 2011 [v1.1]          Page 3 
Also carried out in the project was dose optimisation to ensure the patient was taking the correct 
dose via the least number of tablets, such as ensuring the appropriate dose of [medications]. Drugs 
were also stopped where appropriate e.g. [medication] where the stop-date had not been clearly 
documented 
Changes to communication and increased awareness 
Another major identified impact centred on the changed nature of communication between care 
providers – across different sectors and between different organisations – coupled with a general 
increasing awareness of the role that pharmacists might be able to play: 
The quality of information transfer is being improved and a pilot to involve community pharmacists 
to do targeted MURs for patients is currently underway. Guidelines have been produced by 
secondary care pharmacists and previously these would have had a secondary care bias but due to 
the closer collaboration between primary and secondary care, greater emphasis has been on GP 
prescribing.  Education of GPs by hospital consultants has occurred, though the impact of the 
guidelines in primary care is yet to be assessed 
We have been working with the pharmacy and IT departments in the local hospital to improve and 
standardise discharge letters 
We have facilitated discussions between community pharmacies and [institution] to resolve issues. 
Often the [institution] is not aware of the different options available in their medication supply. 
They have been provided with ‘green bags’ and advice on what medication and information to 
send into secondary care with residents. This should ensure that all relevant information stays with 
the resident while they are in hospital 
The reconciliation of medicines on admission and at discharge supports accurate communication, 
both from and to primary care. It also prevents delays in discharge due to medication issues. A 
recent example of this was seen when a patient was admitted on [medication], the dose of which 
had recently been changed. This wasn't picked up on admission and a higher dose was prescribed. 
Clinical staff estimate the length of stay was increased by four days – this would not have 
happened with a pharmacist reconciling the medicines 
One useful piece of evidence was that dispensed medication often did not reach the patient. This 
evidence allowed me to ask for a visit by a pharmacy porter which was agreed and now we have a 
twice daily visit. Therefore, patients receive their medicines in a timely manner and it is less likely 
to go missing 
The PIP has highlighted that patients/customers have very little idea what services community 
pharmacies can offer, and even if they have heard the ‘name’ of certain services they do not 
actually know what the provision entails. It has provided a good starting point for using the views 
of patients/customers in the planning of, and better patients directed, ‘pharmacy needs 
assessments’ 
Nursing awareness is vastly improved and senior nurses are now trying to ensure juniors are aware 
to transfer medication 
Improved efficiency and reduced errors 
Next, respondents noted that through the PIP they had achieved much greater efficiency in delivering 
their services. Linked to this was the sense that more efficient and well-run services had fewer errors 
and protected patients more effectively: 
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Efficiency of medicines delivery has improved as the vast majority of the prescriptions are sorted 
out one day and in advance therefore when patients say “I have run out” there is no rushing 
around trying to organise a prescription 
Good practice was embedded by introducing a two year cycle of audit which introduced more 
process into prescribing and dispensing [medications] safely 
With clearer procedures, less time is wasted in the clinic setting. This leads to shorter waiting times 
for patients and a lower level of stress for pharmacists 
I have a discussion regarding medication on a regular basis with the prescriber in the team. The 
patient's own medication is always re-used when possible. {Staff] are able to largely leave the 
medication issues to me and as a result this improves efficiency 
There is much less time spent chasing doctors to amend medication on admission, change doses to 
optimise therapy, prescribe in clinic and make additions or amendments at discharge 
The [new way of working] is helping to meet the increasing demands for a quicker patient 
turnaround and the increased workload this creates in the face of cost saving demands. It is 
helping to work towards reducing junior doctor working hours while still keeping the system safe 
Errors in prescribing are now more likely to be discovered and lessons can be learnt from these 
rather than go unnoticed as before 
Patients have better access to their prescribed medication and therefore, fewer doses are missed 
Ensuring that patients’ own medication follows the patient means it is not left in their previous 
locker for another patient to be given incorrectly 
Accurate medication reconciliation on admission has ensured that the patient has continuity and 
has reduced missed doses of regular medication 
Return on investment 
A number of respondents were able to provide a measure of impact in terms of the return on 
investment they had demonstrated. For some this was identifiable in financial terms – for others it was 
noticeable in a range of perhaps more nuanced ways: 
The project is still very much in the early stages but has generated projected savings of £13k so far 
We suggested a large number of prescribing changes – adding medication, stopping medication or 
dose changes – and made 297 interventions in total. The estimated annual savings of the accepted 
changes is £4,722 or £143 per resident 
The results at the nine month stage have seen 120 patients reviewed, 211 interventions made, 19 
reduced hospital admissions and savings in the region of £19,000 
The new approach which is far more clinically driven, has contributed to reduce waste in the 
system which prior to the audit will also contributed to increase to our medicine budget 
Different administration methods may allow for cost savings for some treatment regimes but cost 
for other treatment regimes may be higher due to more expensive drug costs necessary for single 
daily administrations outside hospital vs multiple daily administrations in hospital 
The PIP has reduced waste of occupied beds and hospital nursing time by patients who are well 
enough to be managed in the community 
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Limited or no impact reported 
Respondents were honest enough to acknowledge that the news wasn’t entirely positive. A 
considerable number remarked that it was either too early to tell and couldn’t identify impacts, or that 
for other reasons their PIPs had been delayed and/or only partially completed: 
The lengthy approval process has delayed timescales. It is too early to assess outcomes 
The project is shortly to be implemented so at this time it is too early to assess any direct outcome 
in relation to patients 
The process of delivering on my PIP is on-going. Work is being undertaken – e.g. business case 
development, options reviews etc but the problem is not solved 
The impact has thus far not been measured due to the delays in getting started. We are still 
collecting data since we did not start early due to unforeseen circumstances. However from the 
data so far collected, it is very difficult to know the long term impact of the project after patient is 
discharged from hospital unless the patient is re-admitted later to the hospital 
The PIP is still ongoing, as the resource has not been finally agreed 
The original aim has been partly completed 
During this year, my PIP has not taken off the ground at all! 
Different reasons were offered by way of explanation, variously described as a series of blocks on 
progress – whether political, technical or cultural: 
Progress has been slightly delayed during the reorganisation of the NHS and appointment of new 
Health Board chief pharmacists and a new chief pharmaceutical officer 
The consultant who was in charge of the team was not involved in the discharge form and did not 
have ownership. With hindsight he should have been involved before the form was used 
Due to problems with the launch of the hospital discharge documents the project is still in progress 
The PIP is still in process as since switching [regulators] we have had to do additional work and the 
reaccreditation meeting will now be held in May 2011 
We are continuing to further the project over the coming months by removing obstacles caused by 
some individuals 
It has been limited due to the resignation of my area manager and severe staff shortages 
The major benefit of this project on patients has yet to be realised. This is in part due to the fact 
that it soon became apparent that to successfully complete this work and enable it to be 
implemented we would require a consultant on the multidisciplinary group I was leading 
The delay in implementation has been for a number of reasons including failure to get funding for 
a pharmacist as part of an invest to save bid, guidelines needing amending and acute staff 
shortages have diverted my time. All of these were independent of the leadership course 
Organisational change has increased the number of individuals involved in the decision making 
process and brought conflict between sites that work very differently. This is being worked through 
but slowing down processes somewhat 
The theory is still good and two of my three consultants are very happy to support this but the 
senior consultant has not approved the project. I am slowly working to circumnavigate this person 
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2.1.2 Impact for the organisation  
In addition to the overall impacts identified above, respondents specifically noted a number of issues 
that were pertinent to their sponsoring organisation. Firstly they noted that better collaboration across 
sectors and within multi-disciplinary teams had led to waste minimisation: 
The use of patients own medicines, currently discarded on this site has reduced waste  
Currently evidence shows that 30-50% of medicines are not taken as intended  
Closer collaboration between healthcare providers across primary and secondary care has worked 
and has the potential of reducing waste for future projects 
Less medication has to be re-dispensed as the original packs follow the patient to the ward. Drug 
histories are easier to take as the patient has their medication with them. This reduces pharmacy 
staff time. As the medication follows the patient through, less has to be dispensed on discharge 
and this reduces waiting time for discharge prescriptions 
Linked to this was the sense that better communication had impacted positively on hospital acquired 
infections: ‘The new way of working reduces the risk of patients acquiring hospital acquired infections 
whilst unnecessarily in hospital. It reduces the risk of patients transferring their infection to other 
patients who have to be in hospital when the infected patient doesn't’. Improving poor administrative 
practice was also identified: ‘A reduction in poor administration has resulted, alongside more support 
for patients with poor memory from [services]. Blood tests are followed up in a more timely manner 
post discharge – old drugs are removed to prevent using old and new medications’.  
Finally, respondents noted that their PIPs had helped to reduce the ‘postcode lottery’, an all too-
common feature of the NHS: 
The PIP reduces the inconsistency whereby many English hospitals provide this service and patients 
on the Welsh border managed by Trusts in England have this set up using Welsh district nurses but 
areas further into Wales do not 
The reviews also identified variation in prescribing between practices which were then raised with 
the prescribing lead GP to action 
2.1.3 Ambition and intention for the PIP 
When asked about their current ambitions and intentions for their projects, two themes emerged from 
the questionnaire responses. The first centred on the need for ‘buy-in’ to both the process and 
outcomes of their PIP: 
The next leadership challenge will then be steering the department through the process of 
actioning these proposals and achieving the desired outcomes 
Continue to further the project over the coming months by removing obstacles caused by some 
individuals. Drug protocols for administration via various mechanisms in the community need to be 
drawn up for practical agreement with other members of the [team]. Referral processes and 
clinical responsibility for the patient needs to be ironed out. Collaboration with UK initiatives to 
record outcomes is also needed 
I still need to get a consensus from all the clinicians involved to enable the policy to move forward. 
The policy is agreed across the Health Board now, but is only followed by clinicians to varying 
degrees 
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I am hoping that having seen the data from [place], where the project is based, [the organisation] 
will consider rolling it out as a useful tool to direct the development of services and customer care 
The second theme focused on the vertical integration required to enhance and further the aims of the 
PIP: ‘I have increased involvement of community pharmacists to carry out targeted MURs as 
assessment in hospital is not the most ideal environment. I’m using this project as a stepping stone to 
more closely integrate primary and secondary care’; ‘Work is in progress with Strategic Leads who are 
enthusiastic about taking this further and continued linking of all community services – making 
pharmacy medicines management and essential component in improved patient care in the 
community’. 
2.2 OVERALL CHANGES 
In addition to specific questions on their PIP, the pharmacist respondents were asked to comment 
more broadly on the overall impact that the programme had made to their leadership practice. A 
number of themes emerged from the analysis undertaken. 
2.2.1 Leadership challenges 
Principally, respondents noted that despite the very positive influence that the course had on them, 
there still exists a series of challenges for them as leaders. Several issues in particular came to the fore. 
Securing and maintaining the consent of other professionals 
By far and away the greatest leadership challenge identified by the pharmacists was in respect of 
engaging with those outside their typical sphere of influence, and more broadly exhibiting influence 
and authority: 
Networking across the primary, secondary and tertiary health provision borders was rather 
daunting at first but having taken the initial step of making presentations to both the 'uninformed 
lay man' and my 'interdisciplinary colleagues' I have found that with the project as my 
'springboard' or 'talking point' the potential for leadership in the area relating to my project is 
huge 
Trying to get the consultant interested and on board with process after accepting that potential 
impact would be diminished without consultant involvement 
The challenges for me were believing I had a good idea, getting this recognised within the existing 
management structure and developing relationships outside of pharmacy We encountered 
challenges from the [senior manager] who was keen to outsource the [course]. It meant that we 
had to get a robust case in order and to return the challenge back as to why [they] didn't want to 
continue with our [course]. Through perseverance and a comprehensive case we managed to win 
over the [senior manager] 
Trying to be heard in a multidisciplinary group of established strong leaders has been my biggest 
challenge. Everyone is very busy, and trying to make [medication] their priority (even for an hour 
long meeting) has been difficult 
Making sure senior staff are behind the message is the most important factor in encouraging 
culture change as they encourage their junior colleagues 
I need to ensure that I devote my time to producing quality outcome data for specific projects with 
stakeholders who are easier to work with in order to use it as a springboard to influence those 
more difficult individuals, rather than spreading myself too thinly 
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Actually delivering change in the way information is completed depends on the way that clinicians 
work. There needs to be a change of process right down to the secretary involvement in order for 
change to happen 
Certain nursing staff felt that any medication related issues should be sorted out by pharmacy 
only. Getting the message across has been difficult to achieve in certain circumstances. A culture 
change was required and in many cases, nurses are becoming more responsible for patients own 
medication 
Trying to effectively engage with people outside my usual sphere of influence has been my biggest 
challenge. This has involved trying to effect change in an environment where I'm not known and so 
I have to build trust from scratch 
My biggest challenge has been a consultant with another agenda to my own. Despite coaching 
and discussing this with colleagues, I have been unable to counter this. I have realised from the 
programme to accept defeat and am learning ways to deal with this and methods of 
circumnavigating my challenges 
Maintaining a good relationship with our clinical lead is very difficult 
Working with a consultant who has very strong opinions and is quite dictatorial is difficult 
In trying to standardise regimens and practise from two different hospitals I have found that 
asking people to accept changes can be difficult as they see this as criticism. This was especially 
relevant when upgrading guidelines to policy when consultant challenged content on several 
occasions. Two group members took this personally and I had to spend some time discussing the 
process we were going through and the benefits to keep them on board and maintain their 
enthusiasm 
The nature and structure of business in the NHS was offered by way of a partial explanation as to why 
some of these barriers existed: 
Accepting the difference in pace within the different organisations is difficult 
The NHS re-organisation meant structures have been uncertain and decisions have been very slow 
Leadership by delegation is not leadership. Having influence and authority is necessary to drive 
change. It is difficult to know who the main drivers are for change 
Finance based leadership of the NHS is a significant challenge as managers have to justify their 
utilisation of resources on quality issues which don't immediately release dark green dollars 
In addition, a specific issue around the relationship between change and the pharmaceutical industry 
was raised: ‘There has also been unexpected resistance to the guidelines as a result of drug rep 
pressure on consultants which needed to be resolved’.  
Having enough enthusiasm, energy and time 
Of almost equal importance was the fact that respondents were challenged by the amount of effort 
required to deliver their PIP, as well as their ‘day-job’: 
Maintaining enthusiasm both personally and within the team has also been a challenge which I'll 
admit has not always been successful 
Trying to drive the project forward in a climate where workload is increasing exponentially and the 
focus is almost entirely on cost savings against a background of NHS change where personal job 
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security is still unknown and line management is changing or non-existent is hard. Not a good year 
to focus on this course 
The biggest challenge is to maintain motivation between [programme] days, especially with the 
pressures of day to day work 
Time management – reviews are very time consuming, given the numbers of patients taking 10+ 
medications. This has become part of my job as the reviews have become integrated into the local 
medicines management targets for GP practices but still is a large time commitment for all 
pharmacists carrying out the reviews 
Working in community pharmacy means that the work-load is so huge, that running any project is 
a huge challenge, so time management has been a major challenge 
Making time during my busy working environment to keep committed to process 
Time pressures led to the project never taking a high priority during my working day 
Keeping focused on the end results and what we are trying to achieve – not getting sidetracked 
with other issues 
Time management including time spent on the project and during the project the time spent 
recording data vs. carrying out reviews 
Ensuring alignment with strategic direction 
The ‘need to see the big picture’ was identified by respondents as a real challenge in the delivery of 
their PIP, and more generally in their roles: 
Sometimes you need to step back and assess the whole picture. As a leader it can be as beneficial 
to admit one is not able to achieve all ones’ objectives, but one can continue to look for the 
positive outcomes and small gains 
Until all pharmacists step out of their silos and see the ‘Big Picture’ following the patient journey 
and understanding patients better, patients will still be harmed 
Needed to ensure that any changes resulting from the implementation of [the new role] were in 
line with the strategic direction of both our own health board and also WAG 
A greater understanding of how myself and my team fit into the bigger picture 
A paper on the 10+ medications review was submitted to the medicines management board and 
incorporated into the national [programme]. Based on this paper polypharmacy reviews were 
listed as one of the top 10 recommendations for LHBs to target in 2010 and also as one of the on-
going performance accelerator targets 
Stepping back from overall control 
Being challenged to delegate more effectively, as well as cede control to others in appropriate 
circumstances, was commented upon. Pharmacist respondents made the following observations: 
Once the consultant was on board accepting I would be required to relinquish some control over 
process was a real challenge 
I have had to overcome frustration with the speed of progress of this project at times but it 
became apparent that the impact of the group's work would be much diminished without input 
from the consultant and access that they can give us 
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Not being able to complete the project within time frame due to external issues has taught me 
patience as a leader, sometimes you need to step back and assess the whole picture 
It has also involved me in trying to do the best for the group objective sometimes to the detriment 
of my own personal wishes and feelings 
My main leadership challenges have been confidence in the face of those I often falsely perceive as 
having more "right" to an opinion and the need to ensure that others take responsibility rather 
than stepping in and overwhelming myself 
I am learning to delegate and give responsibilities to colleagues for them to take on audits and 
other tasks 
Moving from a style of 'manager' to leader 
Bureaucracy 
Finally, a range of bureaucratic and administrative challenges was noted: 
Bureaucratic procedures for policy approval have been barriers 
Delay in setting up the approval mechanism for policies/procedures in a new organisation 
[Managers] are often restricted by the policies and procedures of the company they work for and 
cannot individualise processes to allow for local differences 
Mixed with rigidity within management structures and pressure to get the day job done has stifled 
my creativity and innovation over the years 
Also the requirement to keep producing a business plan that was essentially the same throughout, 
but needed updating or changing depending on the recipients 
2.2.2 Opportunities identified 
Alongside the challenges, participants also suggested a number of more positive opportunities that 
they had identified after the programme. For a number of respondents, the generic benefits of the 
programme were obvious: 
It made me approach individuals with greater confidence than I would've done before the course. 
It also encouraged me to be more challenging 
The need to acknowledge success not only in myself by in others has been an important learning 
point. I have used this particular learning to good effect and feel it has made quite a difference 
Leaders need to be credible, this project is linked solely with patient safety and quality and 
therefore the message has been relatively easy to sell, getting people to realise that there is a 
problem has been difficult on time , but generally all practitioners have responded well to our 
requests to review their practice 
Therefore, I found to get the message across, I learnt how to judge the appropriate time to ensure 
the message gets across.  In some cases, it was necessary to implant a new process with only a 
limited number of people being told. So long as the process was simple and the promotion material 
placed in the relevant area, they were quickly taken up 
More specifically, the principal opportunity and benefit identified focused on the new partnerships 
that had emerged from the scheme. Respondents often saw this in terms of more effective 
collaborative working: 
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Development of my interest in PIP is now growing and I hope by summer to undertake another 
audit in collaboration with one of the consultant 
Senior medical and nursing teams recognising they need to work with me to get the service we 
want 
Opportunities to identify this initiative and prove that the primary care contract can, when used 
synergistically, produce excellent results and services for patients. Finding a way to get this 
message out there, linking up with new intra-organisational networks  
The opportunities for more collaborative working if we get this right are huge. I believe Community 
Pharmacy has an integral part to play in the delivery of the wider NHS agenda and delivering this 
scheme would enable us to show that with some evidence 
Opportunity to work across primary and secondary care interfaces 
As a leader I need to be very aware of 'taking people with me' rather than 'blazing ahead' with 
huge enthusiasm in a way that might find me in the company of a few fellow enthusiasts and not 
many other people! 
The project group has recruited a keen community pharmacist to take part in a pilot of assessing 
patients which will be rolled out if successful 
It has also involved me in assessing what is the best way to challenge different people in different 
circumstances in order to obtain best outcome for team 
Linked to the theme above, another benefit that was derived from the programme centred on having 
the opportunity to listen to a new set of voices: 
The networking within the [group] has been strong and we have been able to link into each others’ 
projects, to bring elements of various peoples work to our own day to day ‘jobs’ 
Networking opportunities have been invaluable both in terms of the project ideals and my own 
personal leadership goals 
It has been very useful to participate in this course with pharmacists from other sectors of the 
profession. It has allowed us to build links between pharmacists in [the region] 
Good opportunity to link with other members of the multidisciplinary team including general 
managers and community staff 
Personally taking a lead on the project and writing the papers publicising the project which has led 
to making links with other departments/health boards to share experiences and advise on starting 
the project 
2.2.3 How could pharmacists enhance their impact? 
The final section of the questionnaire asked respondents to reflect on what would need to happen in 
order for the profession to optimise its impact. Five major themes emerged when these answers were 
analysed. 
Get your voice heard 
For significant numbers of participants, ensuring the pharmacists’ voice is heard more powerfully 
through debates was identified as important. They felt this could be achieved either by being more 
forthright and/or more prepared to take risks in ways that would not have been envisaged before the 
programme: 
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The learning from the leadership programme has I feel made me a better, stronger leader more 
ready to "stand up and be heard", more confidence to voice my opinion and in myself and my own 
abilities 
This leadership journey has required me to show more determination in sticking with an agreed 
plan but also to show some flexibility to try and move it forward 
All pharmacists representing our profession need to be leaders, to set an example and be 
courageous enough to represent our profession in potentially intimidating environments. An 
esteemed ex-healthcare "manager" who presented early in the course said of pharmacists that 
they never give him any trouble, never banged on his door and was quite challenging to the group. 
Pharmacists are excellent healthcare professionals and now need to bang the door and integrate 
fully so that "managers" of the above ilk who obviously have not explored getting the best out of 
the resource they had, get the message that our profession can and already does, contribute 
hugely to the healthcare agenda 
In terms of leadership it is sometimes a battleground to get your voice heard. Pharmacists tend to 
think alike but may have different views on how to do things. I used to back down and withdraw if I 
am not getting heard 
As a pharmacist I feel I have stepped up professionally to lead this project and others involved in 
the project to showcase what pharmacists can do. I feel other pharmacists need to take this step to 
demonstrate to others and other professions what pharmacy can offer. Without this pharmacy will 
remain on the whole a profession which is reactive to a doctors work instead of taking forward 
new initiatives 
I'm taking small steps so far on my leadership journey. I need to take the plunge and become more 
visible and willing to take risks. Change needs to occur in the organisation and this can only occur if 
individuals such as myself are willing to radically change. There are risks in the current financial 
climate but these risks bring opportunities that I am in a prime position to explore and develop. I 
just hope that I'm brave enough to have the conviction to do so 
I need to sell myself as a pharmacist and a leader more and have confidence in my skills 
It has fundamentally changed the way I think, in terms of allowing myself "no excuses" and to "just 
get on with it!" 
I believe that if pharmacy does not 'grab' the opportunity it has been given now because of the 
climate of change and redesign, we may not be given the chance again for many years. I also 
believe that the professional body, unless it can actively demonstrate to the profession that it has 
an important role in helping pharmacists have an impact in service change and integration it too 
will not be given such a good opportunity to do so 
Communicate more effectively 
There were two particular issues identified when it came to the overall theme of pharmacists 
communicating more effectively. The first of these centred on a need to improve information transfer 
– between pharmacists in different settings, and between different professionals, often those in the 
same team: 
There needs to be much better information transfer from secondary to primary care and vice versa, 
including involvement of community pharmacists. In addition, failings in the system needs to be 
formally identified and steps taken to address these 
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Community pharmacy needs to be consistently proactive in contacting GPs where potential harm 
in prescribed medicines may occur – this will raise the profile of pharmacists as the experts in 
medicines and improve relationships between professions 
Communication between everyone involved in patient care must be improved to reduce harm. The 
1000 lives campaign focused on specific areas but the problems are systemic. Incompatible IT 
systems between primary and secondary care cause problems – accurate information is not readily 
accessible 
It would reduce harm significantly if we in secondary care could access primary care's patient 
information rather than rely on verbal transfer of information 
Providing community pharmacists with limited access to test results etc. would mean the MURs 
could become a more valuable tool in identifying potentially harmful situations. The MURs could 
then be filtered by the prescribing advisor so the GP only receives the most important which need 
GP input thus improving the standing of MURs 
The second element straightforwardly focused on better sharing best practice, much of which had 
been developed through the process of the PIPs: 
Sharing good practice across Wales is a must 
Needs to be a strong communication network to ensure best practice is shared and recognised as 
the 'norm' to be aspired to within the profession. Systems should be in place to monitor 
developments and celebrate successes 
Highlight the contribution of pharmacists in order to reduce harm. Need more regular feedback on 
interventions and actions carried out by pharmacists that reduce harm 
There are many individual projects relating to pharmacy in practice. Most do not get published and 
often as they are small audits, they do not get much recognition on a national level. It would be 
useful for pharmacists from each area in the country specialising in the same field to share their 
data and good practice 
Celebrate the added value of pharmacy involvement 
It was noted that the contribution of pharmacists needs to be more readily identified and celebrated if 
the profession were to enhance its status. There were two particular strands that emerged. The first of 
these was around ways in which pharmacists could positively impact on the ‘culture of waste’ within 
the NHS, and by extension contribute to safety and clinical outcomes for patients: 
Pharmacists must contribute to the waste agenda and evidence that resources are effectively 
utilised, professional leadership within pharmacy must take pharmacists and place them at the 
heart of effective medicines management 
Schemes need to be identified to encourage patients not to hoard medication and increase use of 
patient own drugs in hospitals. There is an overall culture of waste in the NHS by both staff and 
patients which is in dire need of being addressed 
We all need to work together on adherence issues – these are multifaceted and there are no simple 
solutions 
The pharmacy contract needs to move from payment per item to remove the disincentive for 
pharmacists to identify and reduce waste. This will improve tensions between pharmacists and 
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GPs. Primary care and secondary care pharmacists should to continue to work with clinicians to 
improve cost effectiveness and reduce waste 
There needs to be more re use of patients own medication. If patients are unwilling to take 
medication then we need to listen and stop issuing repeat prescriptions 
The issue of medicine waste is dear to my heart during the past year which may due to variety of 
reasons. This problem means that significant quantities of medicines are costing the NHS millions 
of pounds. I have now developed interest in talking to stakeholders to reduce medicine waste in 
the system 
Pharmacy now needs to concentrate on selling the message that whilst we are excellent in 
effectively managing a drugs budget, we add untold added value in terms of improving patient 
safety and clinical outcomes (where the real cost savings are made) 
The amount of waste in medication and resources is hidden. I think that care pathways are key to 
ensuring that pharmacists know where to best focus their skills and not duplicate what is being 
done or could be done by other staff 
I found that small changes to large numbers of patients can reduce a significant amount of waste. 
Also, small changes to reduce time and quality for actions that are performed frequently can also 
cause large service improvement 
A second set of issues centred on raising awareness of the offer from pharmacy, as well as more 
effective integration of the profession in what is provided: 
I still don't feel that the public or boards necessarily understand what we do sufficiently. I think a 
major publicity campaign is needed but also that pharmacists should take advantage of every 
opportunity available, working without funding if necessary (until outcomes can be demonstrated) 
to maximise people's knowledge of us 
Too often we are seen as obstructive. Views of the profession need to be converted through 
practical experience of pharmacists who provide solutions to problems in innovative ways. 
However, people need to be willing to give us those opportunities to start with 
Pharmacy needs to be recognised as an important part of any organisational change at the outset 
and not considered as an "afterthought" 
RPS needs to work to integrate and represent all sectors of pharmacy; I don’t think the "what’s in it 
for me?" has been answered (it hasn’t for me) and lack of a strong leadership body will result in 
pharmacy developments being profit led and un-integrated into the health service 
Develop better partnerships 
The next major identified theme focused on developing better and more sustainable partnerships both 
within and without pharmacy, whether in working across boundaries, or multi-disciplinarily working 
within extant professional teams: 
Whilst community, primary and secondary care pharmacists all have different aspects to the day 
job, fundamentally it is one profession and we should be able to work across the interfaces with 
ease and comfort – bringing new knowledge and perspectives to each speciality 
Pharmacy needs to improve its PR with other healthcare professions and ensure that it has a clear 
defined role 
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We need to break down the barriers between primary, secondary and community pharmacists. 
More collaborative working and also more cross sector training at early stages in careers 
Different surgeries seem to have different ways of working and it would be of great help that all 
worked the same. For example some are more than happy to issue repeat prescriptions from a 
health professional others are not 
All pharmacists would benefit from cross sector leadership and development training of some sort 
Pharmacists need to help to eliminate the variation in patient care between acute and chronic 
settings; between the well informed/ and the poorly informed; across the boundaries that patients 
have to cross e.g. from secondary to primary to tertiary care 
Pharmacy needs to work in partnership with other parts of the organisation and not on its own 
from the outside 
Value positive development opportunities 
Overall, respondents made it clear that the chance to reflect on their practice, network and be 
supported by peers and learn new skills was precious, and something that they valued dearly. The 
importance of such schemes, in their view, was clear: 
From a personal development point of view the leadership course has had a huge impact on me  
I was successful in a job application which resulted in me taking up a part time position with a 
different LHB. This split 50:50 post therefore meant that I had 50% less time at my original base to 
progress this project. This, interestingly, was wholly down to the leadership course. I would have 
been unlikely to have applied for the job if it wasn't for my coaching session with [coach]  
I have re-discovered my "creative" side which had become suppressed following years of scientific 
study and ways of working. This has given me a new and different strength to use in my leadership 
role. I believe the project, the leadership course and the learning points from it have been a pivotal 
turning point for me 
I feel I am now much better able to undertake and deliver my leadership role having undertaken 
this leadership course 
This course has been invaluable to my leadership development. I have learned much I didn’t expect 
as well as thing I did. For pharmacy to take its most useful and effective place in patient care this 
type of course and learning is essential. 
The work I have done through the project, and the increased 'validity' the leadership programme 
and other developments seem to have 'endowed' on me as a pharmacy professional, seems to be 
opening up new opportunities all the time. 
The process of planning, implementing and reflecting on my PIP has definitely helped me focus on 
issues covered during the leadership course. I feel I have utilised skills which I have acquired and 
developed over the nine months since beginning my leadership journey 
I feel the course has helped to develop me into a more proactive person seeking out opportunities 
and striving to exploit them to their full potential. I have also dropped the negative "tried it - did 
not work" approach and view each new idea with a fresh open mind; overall it has developed my 
confidence in my own ability and potential to reach my goals 
I have been able to reflect on style of working and improve performance in relation to leadership 
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3 | CONCLUSIONS AND AREAS FOR FURTHER CONSIDERATION 
3.1 OVERALL FINDINGS AND CONCLUSIONS 
3.1.1 Key issues and themes 
Taking all of the answers from the two sections of the online questionnaire together, and after 
analysis, four main themes emerged (detail on each of these is provided in Table 2 overleaf):  
Benefits being realised 
There was considerable evidence of better professional practice reported during and after the PIPs, 
whether in terms of standardising service models, improving service efficiency or delivering a return 
on investment; 
Behaviours helping achievement of benefits 
Respondents were able to identify a series of behaviours, attitudes and approaches that helped 
achieve impacts such as securing and maintaining the consent of others, working collaboratively both 
within and without the profession, and engaging with new networks, people and ideas; 
Barriers inhibiting performance 
In addition participants were honest enough to recognise that a series of barriers existed which 
restricted what was able to be achieved including poor communication between providers, not 
having enough energy, enthusiasm and time and not being able to progress as planned; 
Implications for the profession 
Thinking about the future, respondents noted that greater confidence in being heard and taking risks, 
an enhanced professional status, and greater awareness among colleagues of pharmacy’s offer would 
have tangible benefits. 
3.1.2 PIP and the programme 
In order to see the links between the learning on the programme and the PIP, the pharmacists were 
asked how strongly they would agree or disagree with a series of statements in relation to their project 
as below: 
Table 1 | Key themes emerging from online responses 
 
Statement  Cohort Average1 
Having to complete the PIP as part of the programme was an integral part of my 
development as a leader 
3.30 
I can draw direct links between the learning on the programme and delivery of the PIP 3.43 
I would never have made the PIP work effectively without the learning from the programme 2.86 
                                                             
1 n=25 responses. These are calculated based on a five-point Likert scale which was scored as follows: Strongly agree = 5; Tend to 
agree = 4; Neither agree nor disagree = 3; Tend to disagree = 2; Strongly disagree = 1. 
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Table 2 | Key themes emerging from online responses 
 
Overall descriptor Constituent elements Content 
Barriers inhibiting 
performance 
Potential and actual 
barriers to success  
Blocks on progress including achieving buy-in, vertical integration, 
bureaucracy, inflexible management structures and having a mindset 
closed to change 
Communication between 
care providers 
Improvements and challenges to improved information transfer - 
primarily between the community, primary and secondary  care - but 
also between public and private providers 
Impacts cannot yet be 
identified 
Such issues as 'too early to tell', 'don't have the right data to 
determine impacts', 'project delayed', 'project only partial 
completed' and others 
Having enough enthusiasm, 
energy and time 
Concerns about the lack of human resources available to deliver PIPs 
in some cases in addition to the 'day job' 
Benefits being 
realised 
Better professional practice 
Increased compliance, better MURs, stopping unnecessary therapies, 
reduction in postcode lottery and others 
Standardise service models 
and practice 
Reductions in unjustified variation across areas as well as equalising 
professional practice to reduce errors and hospital acquired 
infections 
Evidence of return on 
investment 
Impacts determined in terms of both financial and human savings for 
projects and comments on potential implications for the future 
Improved service efficiency 
Evidence suggesting that the impact has reduced poor administration 
and generally improved the efficiency with which services are run 
Behaviours helping 
achievement of 
benefits 
Engage with and secure the 
consent of others 
Pharmacists exhibiting influence and authority with those outside the 
typical sphere of influence who need to be convinced to secure buy-
in 
Identify new partners and 
working collaboratively 
Working effectively across boundaries - whether disciplinary, 
organisational or sectoral. The element of collaboration includes 
stepping back from overall control when appropriate 
Positive development 
opportunity 
Programme and PIP offered an opportunity to make the transition 
from a manager to a leader, time to reflect, facilitate better 
delegation, acknowledge successes and others 
Benefit of engaging with 
new networks and ideas 
Value in having the opportunity of listening to other voices, sharing 
best practice and exploring innovative work practices 
Implications for the 
profession 
Greater confidence in being 
heard and taking risks 
Being much more forthright in getting voice heard and being 
prepared to take risks, as well as seeing the 'big picture' more 
effectively 
Enhanced professional 
status 
Need to integrate pharmacy profession more effectively, recognise 
that pharmacist involvement = added value and develop leadership 
to address these problems 
Increased awareness of 
pharmacy's contribution 
Outcomes focused on raising awareness of patients and other 
stakeholders of the range of services that can be provided 
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3.1.3 Overall impact: your assessment 
The following table provides our assessment of the impact of the PIPs. It is based entirely on the 
information provided in the 25 sets of responses received via the online questionnaire: 
Table 3 | Overall impact of the PIPs 
 
Description Number of PIPs 
All objectives achieved  0  
Most objectives mainly achieved, on-going  4  
Many objectives achieved, on-going  11  
Some limited progress, on-going  8  
Negligible progress, now stalled  2  
 
3.1.4 Responding to the findings 
In order to validate and test these findings, these three assessments (3.1.1-3.1.3) were presented to 
the pharmacists at a meeting at RPS Wales in April 2011. During the session they were given the 
opportunity to clarify any of the conclusions drawn and to discuss the implications for both 
themselves, and for the future of the programme. They were asked to undertake two specific tasks. 
Accounting for the findings 
In the first of these, and on the basis of the data and their experience of delivering the PIP, the 
respondents were required to think about how they could account for the successes and frustrations 
represented in the data (the ‘why and so what’ questions), and what these findings might mean for 
these and future PIPs? In no particular order the quotations below give a sense of the discussion: 
Pharmacists are always a bit humble about what they might achieve 
Did we envisage that all objectives would have been achieved in the time we had available? 
We wanted to finish things even though we recognised part way through that this wasn’t the best 
method for achieving the aims 
Restructuring the NHS had a bit of an impact on strengths and weaknesses – the lack of direct line 
management gave freedom (positive) but a lack of someone to go to (negative) when you needed 
it.  Overall it was a positive 
It was difficult to get policies agreed without a line manager 
Is progressing a project the same thing as progressing you as a leader? The whole point of the 
project is a means to an end – it’s more important to develop pharmacy leaders than it is to 
develop the objectives from a project 
Chaos is an opportunity…‘I just didn’t know who to ask’…and then you get on and do things 
If projects required moving monies and having resource, this might be easier into the future once 
we’ve got used to the new structures 
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If you’ve had negative experiences previously this can knock you 
You haven’t had the benefit of the learning to help the project succeed at the outset which you 
have at the end 
My employer couldn’t care less about what I did 
It’s less about the project than it is about the learning. It doesn’t matter whether you achieve the 
objectives – that wasn’t the point 
It has to go along in parallel with what you do 
The project wouldn’t have been as good had I not been on the course  
The learning from the programme affected more of our normal practice than specifically relating to 
the project 
You shouldn’t get the PIP out of proportion 
The choice of project depends on who you are trying to convince. You might say that ‘if you release 
me to go on this course, I’ll deliver a project for you’ 
It depends on how you evaluate and capture success. The directly measurable bits may not come 
forward in as positive a light as they might if we see these in terms of leadership development 
My organisation weren’t interested in whether the project was successful or not 
3.1.5 Future proofing and implications 
Reflecting candidly on the whole process, respondents in the discussion group were then asked to 
identify the key learning points and messages that they would share with both next year’s cohort of 
pharmacy leaders in this programme, and the Chief Pharmacist, Minister and other senior policy 
makers. The boxes on the following two pages provide an account of the suggestions that were made. 
3.2 AREAS FOR FURTHER CONSIDERATION 
Taking all of the information together, in our view there are three ‘areas for further consideration’ that 
the evidence points to. These are not formal recommendations but questions which may help to 
optimise the impact that the PIP, and the programme thereafter, is able to have for pharmacists, the 
RPS and NHS Wales.  
3.2.1 Applying for the programme 
In order to secure the right kinds of outcomes it is important to ensure that there is clarity about the 
objectives of the programme, the organisations supporting it and the individual pharmacists 
participating in it. There is scope for formalising the application processes to the programme in order 
to achieve this greater clarity, and in doing so more effectively ensure that the right individuals from 
the right organisations can benefit from the input. The following questions provide an insight into the 
kinds of areas that might be considered here: 
- How well does the current application process function? 
- What selection criteria are in place for accepting people onto the programme? 
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  What key learning points and messages you would share with… 
1. …next year’s cohort of pharmacy leaders in this programme? 
Be ambitious 
Take it outside your comfort zone 
Choose something that is practical, challenging and ambitious 
Be open minded and think outside the box 
Be open to ideas/comments.  Focus may change but objectives can be achieved 
Be cautious 
Keep it manageable within your control 
Keep it small – don’t try and involve too many others 
Choose something in line with your current work ‘direction’ 
Make it part of your job 
Choose something you would do anyway 
Choose a project you have autonomy over 
The difficulty is seeing where the project fits in with your leadership journey.  This would make it 
worthwhile. 
Wait before choosing a topic 
Don’t pick project too early – identify gaps in leadership skills and pick one which addresses those 
In terms of choosing a project, wait until the course is further progressed and you know where your 
weaknesses are 
Don’t choose the project too soon. Ideas for PDP learning outcomes come first then pick a project that 
will achieve them as well as objectives for your organisation 
See the project as a means to an end 
Think of the project as a tool for your own development - not itself (what do I need to get out of this?) 
The project isn’t everything – it is a tool for putting things learned into practice 
In deciding on a project, be clear about what you will benefit from in terms of leadership 
The best bits were the fluffy bits which were the bits we were scared of at the beginning 
Don’t agonise over it 
There is too much emphasis on the project at the beginning and that stressed everyone out – whose 
fault was this? Is this a function of timing – project comes to early/too late? How important is success 
in the project instrumental in achieving future funding? 
Choose carefully but don’t get hung up on it 
Is it too soon to judge the overall impact? 
It’s difficult to measure patient impact – should we have a ‘Service Impact Project’? Or just an ‘Impact 
Project’? 
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- How would RPS deal with a situation where there are substantially more applicants than places 
available? 
- How important is it to drive up the value of the programme’s brand, and what role might better 
PR and advertising play in making this course a more prestigious development opportunity? 
- Do you understand what is stopping pharmacists who might like to take part from making an 
application, and are you able to mitigate against any of these barriers? 
3.2.2 Relationship between the participant and the organisation 
Of crucial importance in maintaining good working relationships once individuals have been accepted 
onto the programme is an understanding between participants and their organisations. Evidence 
suggests that some respondents have found themselves on the course despite, rather than because of, 
their organisations, with a number pointing to the fact that their employer is unconcerned with the 
What key learning points and messages you would share with… 
2. …the Chief Pharmacy Officer, Minister and other senior policy makers? 
Understand the impact that has been achieved 
Find out about our projects 
Projects and leadership skills that we learned will have tangible impacts 
Patients we’ve dealt with have had a better experience 
Keep an eye out for the progress of our projects 
The impact of the project should not be the sole criteria for evaluating the worth of the overall 
programme – you need to see this in context and take the main messages forward 
Value the contribution of pharmacists 
How do we increase the pharmacy voice? 
Have faith in pharmacy development – we’ve got evidence from the projects to prove that we can 
deliver  
Recognise the benefits to patients from better pharmacy practice 
Help to make the linkages with us 
Value the personal development of potential leaders 
The project is not the be all and end all of the course – qualitative improvements through learning 
(although not measurable) are important, and may be more important 
Work with us to enhance the status of pharmacy 
Recognise the fact that we are clinicians in our own right 
Think about pharmacy in every development 
Ask us where and how we can impact 
Look at where we can take this work further 
Identify projects that we can undertake that will help deliver broader leadership outcomes 
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outcomes from the PIP and their personal development. This is clearly not an optimal arrangement. In 
order to change this way of working to benefit of all parties involved, the following questions should 
be considered: 
- How far are sponsoring organisations aware of the aims and objectives of the programme 
before participants are sent? 
- To what extent is there a contract/compact between individuals, their organisations and RPS?  
- How far up the management structure should there be ‘buy-in’ to the programme from the 
sponsoring organisation? 
- Is there any exchange of information between RPS and the organisation about progress at any 
stage during the programme? 
- How far is it possible for sponsoring organisations to influence the choice of PIP? 
- How well aligned are PIPs with the sponsoring organisations strategic and delivery objectives 
and not just an interesting add-on to current practice? Whose responsibility is it to ensure that 
there is a match-up? 
- Is there any form of ‘celebration event’ at the end of the programme to report on achievement 
to which senior managers and chief executives from sponsoring organisations could be invited? 
How influential could this type of event be, and would it be possible to make attendance a 
condition of acceptance on the programme? 
- Whose responsibility is it to continue the personal development journey after the programme 
finishes? Is there clarity over respective roles for the individual, the sponsoring organisation 
and the RPS? 
3.2.3 The role of the PIP in the programme overall 
Finally, in terms of impact the role of the PIP in the programme is central. It offers the best opportunity 
for gathering measurable data on the impact that the pharmacists are able to achieve. However, 
during the course of discussions two very clear, and opposing, views were expressed. Some 
participants felt that the PIP was solely a means to an end, and whilst useful in providing a test bed for 
new approaches to pharmacy leadership, ‘collecting evidence about the PIPs’ outcomes is not 
especially important’. On the other hand, a number of individuals noted that the PIP had given them 
additional credibility and validity in their professional life. This was based on their assertion that 
measurable outcomes from the PIP had provided them with information to support their claim that 
‘you can trust us because we’ve got the evidence that we can deliver’. Reconciling these two 
viewpoints is of central importance in clarifying the role of the PIP within the programme, and 
clarifying the expectations of stakeholders without the programme. The following questions are 
pertinent here: 
- How best is it possible to optimise the impact of the PIPs? 
- How helpful would it be to clarify the overall role that the PIP plays in the programme? 
- What are the expectations of those looking in on this programme around the PIP? 
- Should the PIP be scheduled later in the programme to allow time for participants to ‘bed-in’ 
and use their new learning more effectively? 
- How important is it that measurable changes are achieved within the timescale of the 
programme? 
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- How far should external partners like WAG be allowed to identify relevant topics for PIPs? 
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APPENDIX I | Questions asked in the online survey 
Section 1: PATIENT IMPACT PROJECT (PIP) 
1. To what extent does the summary above accurately reflect what has actually been delivered by your 
PIP? Please describe any changes in the box below.  
2. What has been the impact of your project on patients? Please provide about 250 words in your 
response. When answering please consider the following: - How do patients flow through the system 
from community pharmacy, through primary care, and onto secondary and tertiary care? - Can you 
provide any evidence on how patient flow can be improved in relation to chronic disease 
management? - What evidence do you have to support the impact you've seen?  
3. What has been the impact of the project on service provision for the organisation in terms of (a) 
waste, (b) harm, (c) unjustified variation, and (d) anything else?  
4.  Overall, in relation to your project, how strongly would you agree or disagree with the following 
statements? (Strongly agree; Tend to agree; Neither agree nor disagree; Tend to disagree; Strongly 
disagree) 
a. Having to complete the PIP as part of the programme was an integral part of my development 
as a leader  
b. I can draw direct links between the learning on the programme and the delivery of the PIP  
c. I would never have made the PIP work effectively without the learning from the programme  
5. What is your ambition and intention for your project at this stage?  
Section 2: OVERALL 
6. From the experience of working on your project and trying to innovate and introduce service change, 
what have been the personal leadership challenges that you have encountered?  
7. From working on your project please give specific examples of systemic leadership that you have 
encountered (a) in terms of challenges, and (b) in terms of opportunities?  
8. For the profession to enhance its impact on service change and integration, and from your own 
leadership journey and this project, what would need to be addressed in terms of (a) harm, (b) waste, 
(c) variation, (d) your leadership and behaviour, and (e) anything else?  
9. Please add anything else you'd like to say in the box below. 
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